Embecta Corporation (EMBC)

Embecta's stock price has been impacted by weaker-than-expected Q2 2026 results, leading to reduced full-year guidance and a dividend cut. The company announced a share repurchase program and agreed to acquire Owen Mumford. The stock has seen a decline over the past year.

The provided information does not explicitly detail any specific demand seasonality for Embecta Corp.'s products and services. Market dynamics, competitive landscape, and healthcare policies are more significant drivers of demand than seasonal patterns.

Embecta Corp. is a global medical technology company focused on diabetes care solutions, including insulin delivery devices like syringes and pen needles. They also offer digital diabetes management solutions and contract manufacturing services.

Embecta has a global presence, selling products in over 100 countries. Its manufacturing facilities are located in the United States, Ireland, and China, with its global headquarters in Parsippany, New Jersey.

Embecta's brand reputation has likely been affected by its financial performance, including a drop in stock price and a dividend cut. An ongoing investigation into potential securities law violations could also pose a risk to the company's reputation.

Embecta Corp. has significant institutional ownership, ranging from approximately 93.8% to 98.5% of its shares. Major institutional owners include BlackRock, Inc., American Century Companies Inc, Vanguard Group Inc, River Road Asset Management, LLC, Deerfield Management Company, L.p. (series C), State Street Corp, Jefferies Financial Group Inc., Yacktman Asset Management Lp, William Blair Investment Management, Llc, and Geode Capital Management, Llc. Individual insiders hold about 1.43% of the company's shares.